Telix Pharmaceuticals stock
TLXNASDAQTelix Pharmaceuticals Limited, HealthcareISIN US87961M1053
39Score 39 out of 100, Weak
Price and trend
62 / 100
Price history
−4.6% in one yearThe chart shows daily closes over 2 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 6.2% below it.
Since May 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 53).
The price is 27% below its 52-week high. Largest decline in 2 years: 69% (February 2025 to February 2026).
Chart figures for advanced users
- SMA 50$10.72
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$9.98
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)53
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$6.41
- The lowest closing price of the last twelve months.
- Resistance$12.83
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Telix Pharmaceuticals Limited belongs to the Biotechnology industry (Australia) and, with a market value of $3.18B, is number 98 of 289 companies in its industry on MEQIRI.
- This is an American depositary receipt (ADR).
- In fiscal 2025 it reported revenue of $789.77M (up 0.8% year on year) and a loss of $7M.
Show more
- MEQIRI Score 39 out of 100 (Weak): rank 555 of 702 in Healthcare, median 53.
- The P/E is 99.9 (Biotechnology median 21.7, own median of recent years 165.8).
- Our model puts fair value at $13.59, with the price 31% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 172.9% a year since 2020, Biotechnology median 19.4%.Growth 59
- Analysts expect strong earnings growthUp 63.3% a year through 2028 (estimates from 7 analysts).Growth 59
Weaknesses
- Interest barely coveredOperating profit covers interest only 0.9 times.Stability 42
- DilutionShare count up 31% since 2020.Capital allocation 18
- Negative free cash flowFree cash flow −$57.14M over the last 12 months.Fundamentals 18
The score is held back by fundamentals and capital allocation.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 40 to 39.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
- high price swings
Valuation
Valuation signal
Possible value trapIn our model the price counts as cheap below $9.71 and expensive above $22.65 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $25.15 (cash-flow model) and $2.03 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 9.6%. At 10.6% the fair value would be $11.37, at 8.6% it would be $16.78.
Possible value trap: looks cheap, but score below 50, weak balance sheet.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (21.7).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue fell 6.7% on the twelve months before. Revenue has grown strongly since 2019, at around 147% per year. From 2019 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 53%, operating 2%, net −1%. From 2019 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 19 Feb 2027in 98 days
- Last reported
- 19 Aug 2026above expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 20.0% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- 0.12+2.3%
- Revenue
- $1.41B−0.3%
- Earnings per share
- 0.07−20.0%
- Revenue
- $1.82B−1.7%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +4.5%Revenue guidance of $950 million to $970 million maintained, expected at the upper end of the range; R&D guidance updated to $230 million to $270 million.
“Our full year revenue guidance of between $950 million and $970 million is maintained for 2026. We do, however, expect that to land at the upper end of the range, and we expect continued growth in excess of 20% year-on-year of our Precision Medicine business.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 19 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
One insider bought on the open market in the last 6 months, $14,427 in total.
- Smith Darren CharltonPurchase
7 Sept 2026, Group Chief Financial Officer
- Shares
- 2,071
- Price
- $6.97
- Value
- $14,427
Shares and prices per ordinary share as filed with the SEC, not per depositary receipt.
Prices filed in A$ converted to dollars at the exchange rate of the trade date.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Telix Pharmaceuticals
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 39
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Viridian TherapeuticsVRDN $3.46B47
- Legend BiotechLEGN $3.43B36
- Disc MedicineIRON $3.2B41
- Dyne TherapeuticsDYN $3.19B34
- Acadia PharmaceuticalsACAD $3.14B62
- IDEAYA BiosciencesIDYA $3.04B38
- Xeris Biopharma HoldingsXERS $3.04B55
- Zai LabZLAB $2.94B50
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 14 Nov 2025)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.